Published: May 03, 2010

XenoPort Announces Presentations of New Data for Arbaclofen Placarbil at Digestive Disease Week Meeting

Share This Story

SANTA CLARA, Calif. - (BUSINESS WIRE) - XenoPort, Inc. (Nasdaq:XNPT) announced today that new data from clinical trials of its product candidate arbaclofen placarbil will be presented at the Digestive Disease Week meeting in New Orleans, LA. The following posters will be presented:

Arbaclofen Placarbil, a Novel Reflux Inhibitor, Is Safe and Well Tolerated at Efficacious Doses in Subjects With Gastroesophageal Reflux Disease
Session Info: GERD: Pharmacological Treatment, Wednesday, May 5, 2010, 8:00 a.m. - 5:00 p.m.
Poster #: W1102

Clinical Pharmacokinetics and Pharmacodynamics of Arbaclofen Placarbil, a Novel Reflux Inhibitor, in Subjects With GERD
Session Info: GERD: Pharmacological Treatment, Wednesday, May 5, 2010, 8:00 a.m. - 5:00 p.m.
Poster #: W1105

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPort's product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity and Parkinson's disease. To learn more about XenoPort, please visit the web site at www.XenoPort.com.

XenoPort is a registered trademark of XenoPort, Inc.

XNPT2C